Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials

Respiratory Medicine

Volumn 113, Issue , 2016, Pages 74-79

  Richeldi, Luca ^a   Cottin, Vincent ^b   du Bois, Roland M ^c   Selman, Moisés ^d   Kimura, Toshio ^e   Bailes, Zelie ^f   Schlenker Herceg, Rozsa ^g   Stowasser, Susanne ^e   Brown, Kevin K ^h  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITÉ LYON 1   (France)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f BOEHRINGER INGELHEIM LTD   (United Kingdom)

^g BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^h DEPARTMENT OF MEDICINE   (United States)

Author keywords

Acute exacerbations; Disease progression; Forced vital capacity; Mortality; Quality of life

Indexed keywords

NINTEDANIB; ENZYME INHIBITOR; INDOLE DERIVATIVE;

ABDOMINAL PAIN; AGED; ALL CAUSE MORTALITY; ARTICLE; BODY WEIGHT DISORDER; BODY WEIGHT LOSS; BRONCHITIS; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE EXACERBATION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK REDUCTION; ST. GEORGE RESPIRATORY QUESTIONNAIRE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CHEMICALLY INDUCED; DRUG ADMINISTRATION; DRUG EFFECTS; IDIOPATHIC PULMONARY FIBROSIS; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; VITAL CAPACITY;

AGED; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84966283970     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2016.02.001     Document Type: Article

References (16)

1. du Bois, R.M., Weycker, D., Albera, C., et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am. J. Respir. Crit. Care Med. 184 (2011), 1382–1389.
2. du Bois, R.M., Nathan, S.D., Richeldi, L., et al. Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. Am. J. Respir. Crit. Care Med. 186 (2012), 712–715.
3. Raghu, G., Collard, H.R., Egan, J.J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183 (2011), 788–824.
4. Swigris, J.J., Stewart, A.L., Gould, M.K., et al. Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual. Life Outcomes, 3, 2005, 61.
5. Ley, B., Collard, H.R., King, T.E. Jr., Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 183 (2011), 431–440.
6. Collard, H.R., Moore, B.B., Flaherty, K.R., et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 176 (2007), 636–643.
7. Wollin, L., Wex, E., Pautsch, A., et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. J. 45 (2015), 1434–1445.
8. Boehringer Ingelheim Pharmaceuticals, Inc, OFEV™ (Nintedanib) Prescribing Information. 2014 Available at: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Ofev/ofev.pdf (accessed 09.03.15).
9. Boehringer Ingelheim, OFEV (Nintedanib) Summary of Product Characteristics. 2015 February 2015. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003821/human_med_001834.jsp&mid=WC0b01ac058001d124 (accessed 01.04.15).
10. Richeldi, L., Costabel, U., Selman, M., et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 365 (2011), 1079–1087.
11. Swigris, J.J., Esser, D., Conoscenti, C.S., et al. The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual. Life Outcomes, 12, 2014, 124.
12. Richeldi, L., du Bois, R.M., Raghu, G., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370 (2014), 2071–2082.
13. Loveman, E., Copley, V.R., Scott, D.A., et al. Comparing new treatments for idiopathic pulmonary fibrosis - a network meta-analysis. BMC Pulm. Med., 15, 2015, 37.
14. Costabel, U., Inoue, Y., Richeldi, L., Collard, H.R., Tschoepe, I., Stowasser, S., Azuma, A., Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am. J. Respir. Crit. Care Med. 193:2 (2016), 178–185.
15. Richeldi, L., Cottin, V., Flaherty, K.R., et al. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir. Med. 108 (2014), 1023–1030.
16. Karimi-Shah, B.A., Chowdhury, B.A., Forced vital capacity in idiopathic pulmonary fibrosis–FDA review of pirfenidone and nintedanib. N. Engl. J. Med. 372 (2015), 1189–1191.